PEMAZYRE is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Incyte Corporation. The primary component is Pemigatinib.
Product ID | 50881-028_0954b874-3869-42e6-9d21-6a86108bb2ea |
NDC | 50881-028 |
Product Type | Human Prescription Drug |
Proprietary Name | PEMAZYRE |
Generic Name | Pemigatinib |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2020-04-17 |
Marketing Category | NDA / NDA |
Application Number | NDA213736 |
Labeler Name | Incyte Corporation |
Substance Name | PEMIGATINIB |
Active Ingredient Strength | 14 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2020-04-17 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA213736 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2020-04-17 |
Ingredient | Strength |
---|---|
PEMIGATINIB | 13.5 mg/1 |
SPL SET ID: | 9e1f2222-1d89-4e63-989c-ccebe2ab1eb4 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
50881-026 | PEMAZYRE | pemigatinib |
50881-027 | PEMAZYRE | pemigatinib |
50881-028 | PEMAZYRE | pemigatinib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
PEMAZYRE 88895503 not registered Live/Pending |
Incyte Holdings Corporation 2020-04-30 |
PEMAZYRE 88616570 not registered Live/Pending |
INCYTE HOLDINGS CORPORATION 2019-09-13 |
PEMAZYRE 87822632 not registered Live/Pending |
Incyte Holdings Corporation 2018-03-06 |